Research Analysts Set Expectations for SABS FY2026 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Equities researchers at Brookline Capital Markets lowered their FY2026 earnings estimates for shares of SAB Biotherapeutics in a research note issued on Thursday, November 5th. Brookline Capital Markets analyst K. Raja now anticipates that the company will earn ($1.16) per share for the year, down from their prior forecast of ($1.08). The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($1.17) per share. Brookline Capital Markets also issued estimates for SAB Biotherapeutics’ Q4 2026 earnings at ($0.27) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($1.01) EPS, FY2029 earnings at $0.45 EPS and FY2030 earnings at $1.35 EPS.

SAB Biotherapeutics (NASDAQ:SABS) last issued its earnings results on Thursday, November 5th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03.

A number of other brokerages have also weighed in on SABS. Weiss Ratings raised SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Wall Street Zen upgraded SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 10th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.00.

SAB Biotherapeutics Stock Up 2.3%

Shares of NASDAQ:SABS opened at $3.10 on Tuesday. SAB Biotherapeutics has a 52-week low of $2.44 and a 52-week high of $5.15. The stock has a market cap of $282.07 million, a P/E ratio of -2.33 and a beta of 0.67. The business’s 50 day moving average is $3.18 and its 200 day moving average is $3.66. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.01.

Institutional Trading of SAB Biotherapeutics

Several hedge funds have recently modified their holdings of SABS. PNC Financial Services Group Inc. bought a new stake in shares of SAB Biotherapeutics in the 1st quarter valued at about $29,000. IFP Advisors Inc bought a new position in shares of SAB Biotherapeutics during the 2nd quarter worth approximately $151,000. Bank of America Corp DE raised its stake in shares of SAB Biotherapeutics by 424.8% during the 1st quarter. Bank of America Corp DE now owns 55,697 shares of the company’s stock worth $213,000 after acquiring an additional 45,084 shares in the last quarter. Kestra Advisory Services LLC raised its stake in shares of SAB Biotherapeutics by 434.6% during the 1st quarter. Kestra Advisory Services LLC now owns 61,741 shares of the company’s stock worth $236,000 after acquiring an additional 50,191 shares in the last quarter. Finally, Alps Advisors Inc. lifted its position in SAB Biotherapeutics by 54.2% during the third quarter. Alps Advisors Inc. now owns 119,688 shares of the company’s stock valued at $379,000 after acquiring an additional 42,088 shares during the last quarter. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals’ plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.